CN1552879A - Use and obtain of inactivating lumour CHK1 gene anticancer recombined gland virus constituent - Google Patents
Use and obtain of inactivating lumour CHK1 gene anticancer recombined gland virus constituent Download PDFInfo
- Publication number
- CN1552879A CN1552879A CNA031267599A CN03126759A CN1552879A CN 1552879 A CN1552879 A CN 1552879A CN A031267599 A CNA031267599 A CN A031267599A CN 03126759 A CN03126759 A CN 03126759A CN 1552879 A CN1552879 A CN 1552879A
- Authority
- CN
- China
- Prior art keywords
- adenovirus
- cell
- adv5
- construction body
- 931adv5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 title description 9
- 210000004907 gland Anatomy 0.000 title description 6
- 230000001093 anti-cancer Effects 0.000 title description 5
- 101150050673 CHK1 gene Proteins 0.000 title description 3
- 230000000415 inactivating effect Effects 0.000 title description 3
- 239000000470 constituent Substances 0.000 title 1
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 180
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims abstract description 36
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims abstract description 36
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 36
- 239000002299 complementary DNA Substances 0.000 claims abstract description 18
- 238000012217 deletion Methods 0.000 claims abstract 4
- 230000037430 deletion Effects 0.000 claims abstract 4
- 238000010276 construction Methods 0.000 claims description 46
- 230000006798 recombination Effects 0.000 claims description 44
- 238000005215 recombination Methods 0.000 claims description 44
- 239000012634 fragment Substances 0.000 claims description 32
- 108020004414 DNA Proteins 0.000 claims description 27
- 230000008034 disappearance Effects 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 22
- 108090000790 Enzymes Proteins 0.000 claims description 22
- 238000001415 gene therapy Methods 0.000 claims description 20
- 239000013612 plasmid Substances 0.000 claims description 19
- 108091008146 restriction endonucleases Proteins 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 101710199711 Early E1A protein Proteins 0.000 claims description 7
- 108020004999 messenger RNA Proteins 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 238000012408 PCR amplification Methods 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 101710192606 Latent membrane protein 2 Proteins 0.000 claims 1
- 101710109576 Terminal protein Proteins 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 239000013605 shuttle vector Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 91
- 206010028980 Neoplasm Diseases 0.000 abstract description 76
- 210000004881 tumor cell Anatomy 0.000 abstract description 37
- 238000011282 treatment Methods 0.000 abstract description 19
- 238000001890 transfection Methods 0.000 abstract description 12
- 238000000746 purification Methods 0.000 abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 abstract description 6
- 230000007812 deficiency Effects 0.000 abstract description 2
- 230000008521 reorganization Effects 0.000 abstract description 2
- 101150096316 5 gene Proteins 0.000 abstract 1
- 241001135569 Human adenovirus 5 Species 0.000 abstract 1
- 239000003513 alkali Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 49
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 27
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 25
- 230000000694 effects Effects 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 238000005119 centrifugation Methods 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 238000000502 dialysis Methods 0.000 description 13
- 235000015097 nutrients Nutrition 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 238000005336 cracking Methods 0.000 description 10
- 230000024835 cytogamy Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 230000004087 circulation Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 230000009849 deactivation Effects 0.000 description 7
- 230000002147 killing effect Effects 0.000 description 7
- 108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000011435 rock Substances 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 238000013016 damping Methods 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000009126 molecular therapy Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000006209 dephosphorylation reaction Methods 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 206010013183 Dislocation of vertebra Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000012820 cell cycle checkpoint Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 108091036078 conserved sequence Proteins 0.000 description 3
- 230000030609 dephosphorylation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000002934 lysing effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000000064 prostate epithelial cell Anatomy 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 2
- 208000004179 Oral Leukoplakia Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 101150020201 RB gene Proteins 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000000981 bystander Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 201000008557 oral mucosa leukoplakia Diseases 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 108700025694 p53 Genes Proteins 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 101150006084 CHKB gene Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010093502 E2F Transcription Factors Proteins 0.000 description 1
- 102000001388 E2F Transcription Factors Human genes 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 101150010855 cma gene Proteins 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Wild-type ADV5 | ??ADV-TK | ??Δ923-931ADV5/ASCHK1 | |
A549 | |||
The 3rd day | 50% | 1% | 93% |
The 6th day | 100% | 2% | 100% |
The 10th day | 4% | ||
Hela | |||
The 3rd day | 60% | 1% | 94% |
The 6th day | 100% | 2% | 100% |
The 10th day | 4% | ||
U-2OS | |||
The 3rd day | 60% | 1% | 95% |
The 6th day | 100% | 2% | 100% |
The 10th day | 4% | ||
HS700T | |||
The 3rd day | 60% | 1% | 93% |
The 6th day | 100% | 2% | 100% |
The 10th day | 4% | ||
DLD-1 | |||
The 3rd day | 60% | 1% | 90% |
The 6th day | 100% | 2% | 100% |
The 10th day | 4% | ||
MCF-7 | |||
The 3rd day | 60% | 1% | 95% |
The 6th day | 100% | 1% | 100% |
The 10th day | 1% | ||
Vascular endothelial cell | |||
The 3rd day | 60% | 1% | 4% |
The 6th day | 100% | 2% | 4% |
The 10th day | 4% | 4% | |
Lung tracheole epithelial cell | |||
The 3rd day | 60% | 1% | 3% |
The 6th day | 100% | 2% | 3% |
The 10th day | 4% | 6% | |
Prostate epithelial cell | |||
The 3rd day | 60% | 1% | 4% |
The 6th day | 100% | 2% | 4% |
The 10th day | 4% | 5% | |
BMNC | |||
The 3rd day | 60% | 1% | 2% |
The 6th day | 100% | 2% | 2% |
The 10th day | 4% | 6% |
Claims (4)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03126759 CN1243099C (en) | 2003-06-05 | 2003-06-05 | Use and obtain of inactivating lumour CHK1 gene anticancer recombined gland virus constituent |
US10/860,630 US20050079158A1 (en) | 2003-06-05 | 2004-06-03 | Construct of anti-cancer recombinant adenovirus, method for preparing the same and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03126759 CN1243099C (en) | 2003-06-05 | 2003-06-05 | Use and obtain of inactivating lumour CHK1 gene anticancer recombined gland virus constituent |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1552879A true CN1552879A (en) | 2004-12-08 |
CN1243099C CN1243099C (en) | 2006-02-22 |
Family
ID=34321995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03126759 Expired - Fee Related CN1243099C (en) | 2003-06-05 | 2003-06-05 | Use and obtain of inactivating lumour CHK1 gene anticancer recombined gland virus constituent |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1243099C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108048483A (en) * | 2018-01-30 | 2018-05-18 | 中国疾病预防控制中心病毒病预防控制所 | Science recombined adhenovirus HAdV-5 carrier systems and its application |
-
2003
- 2003-06-05 CN CN 03126759 patent/CN1243099C/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108048483A (en) * | 2018-01-30 | 2018-05-18 | 中国疾病预防控制中心病毒病预防控制所 | Science recombined adhenovirus HAdV-5 carrier systems and its application |
Also Published As
Publication number | Publication date |
---|---|
CN1243099C (en) | 2006-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7159304B2 (en) | Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and their use for medicaments for the treatment of tumors and/or cancers | |
US8273344B2 (en) | Recombinant adeno-associated virus expressing human antisense gene CyP2J2 and its preparation methods | |
RU2361611C2 (en) | Designing of carcinolytic adenovirus recombinant, specifically expressing immunomodulatory factor gm-csf in tumoral cells and its application | |
WO1999031261A9 (en) | SELECTIVE KILLING AND DIAGNOSIS OF p53+ NEOPLASTIC CELLS | |
CN102286433A (en) | Obtainment and application of novel oncolytic adenovirus-thymidine kinase genetic construct | |
CN112912389A (en) | Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40 ligand | |
JP6014029B2 (en) | REIC expression adenovirus vector | |
JP6001535B2 (en) | Oncolytic measles virus | |
CN102206613A (en) | Acquisition and use of tumor-selective replicative adenovirus - thymidine kinase gene construct | |
ZA200500047B (en) | Tumor-lysing virus growing selectively in tumor cells | |
CN103484462B (en) | The recombinant adenoviral vector of Survivin promoter regulation CD gene builds and application | |
CN1237177C (en) | Use and obtain of selective inactivating tumour PLK1 anticancer recombined gland virus constituent | |
CN1243099C (en) | Use and obtain of inactivating lumour CHK1 gene anticancer recombined gland virus constituent | |
CN1272440C (en) | Use and constructing method for anticancer recombined gland virus with tumour cell PLK1 as target of medicine | |
CN1237178C (en) | Use and constructing plan of anticancer recombined gland virus with tumour CHK1 as target of medicine | |
WO2006125381A1 (en) | Tumor targeting gene-virus zd55-il-24, construction method and application thereof | |
US20130095558A1 (en) | Process for producing recombinant human endostatin adenovirus | |
US20050079158A1 (en) | Construct of anti-cancer recombinant adenovirus, method for preparing the same and use thereof | |
CN1177057C (en) | Recombinant of viral vector and human tumor suppressor gene, and use thereof | |
CN1769433B (en) | Recombinant vesicular stomatitis virus and its uses | |
US20050271622A1 (en) | Construct of tumor-selective recombinant adenovirus, method for preparing the same and use thereof | |
CN103695556B (en) | The test kit of application in oral carcinoma diagnosis, prevention or treatment and medicine | |
CN103566367B (en) | A kind of oral allergen vaccine and Synthesis and applications thereof | |
Turrell et al. | A herpesvirus saimiri-based vector expressing TRAIL induces cell death in human carcinoma cell lines and multicellular spheroid cultures | |
CN107828819B (en) | Method for constructing recombinant adenovirus by using ANP or IgANP gene, recombinant adenovirus and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Zhou Qi Document name: Notice of conformity |
|
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN TIANDAKANG GENE ENGINEERING CO., LTD Free format text: FORMER OWNER: AONIKESI GENE TECHNOLOGY CO., LTD., SHENZHEN CITY Effective date: 20071123 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20071123 Address after: Shenzhen high tech Zone 1104 biological incubator building room Patentee after: Shenzhen Tiandakang Genetic Engineering Co.,Ltd. Address before: High tech Zone of Shenzhen city in a 1104 biological incubator building room Patentee before: SHENZHEN AONIKESI GENE TECHNOLOGY Co.,Ltd. |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Zhou Qi Document name: Notice of conformity Addressee: Zhou Qi Document name: Approval notice for cost mitigation |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Zhou Qi Document name: Approval notice for cost mitigation |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Zhou Qi Document name: payment instructions |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Zhou Qi Document name: Notice of termination of patent right |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060222 Termination date: 20210605 |